Kolon TissueGene Management
Management criteria checks 2/4
Kolon TissueGene's CEO is Moon-Jong Noh, appointed in Jan 2025, has a tenure of less than a year. total yearly compensation is ₩548.27K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 0.059% of the company’s shares, worth ₩1.80B. The average tenure of the management team and the board of directors is 1.9 years and 4.8 years respectively.
Key information
Moon-Jong Noh
Chief executive officer
₩548.3k
Total compensation
| CEO salary percentage | 100.0% |
| CEO tenure | less than a year |
| CEO ownership | 0.06% |
| Management average tenure | 1.9yrs |
| Board average tenure | 4.8yrs |
Recent management updates
Recent updates
CEO
Moon-Jong Noh (56 yo)
less than a year
Tenure
₩548,272
Compensation
Dr. Moon Jong Noh, PhD, has been the Chief Executive Officer, President and Director of Kolon TissueGene, Inc. since 2019 and served as its Chief Technology Officer since June 6, 2017 until 2019 and served...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | less than a year | ₩548.27k | 0.059% ₩ 1.8b | |
| CEO & Director | less than a year | no data | no data | |
| CFO & Director | 3.4yrs | no data | 0.000010% ₩ 305.3k | |
| Chief Medical Officer | 3.9yrs | no data | no data | |
| Statutory Auditor & Director | no data | no data | no data |
1.9yrs
Average Tenure
56yo
Average Age
Experienced Management: A950160's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 6.3yrs | ₩548.27k | 0.059% ₩ 1.8b | |
| CEO & Director | less than a year | no data | no data | |
| CFO & Director | 3.3yrs | no data | 0.000010% ₩ 305.3k | |
| Statutory Auditor & Director | 4.3yrs | no data | no data | |
| Member of Business Advisory Board | no data | no data | no data | |
| Member of Business Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 8.3yrs | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 8.9yrs | no data | no data | |
| Member of the Scientific Advisory Board | 5.3yrs | no data | no data | |
| Independent Outside Director | 2.1yrs | no data | no data |
4.8yrs
Average Tenure
56.5yo
Average Age
Experienced Board: A950160's board of directors are considered experienced (4.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/08 05:28 |
| End of Day Share Price | 2025/05/08 00:00 |
| Earnings | N/A |
| Annual Earnings | N/A |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Kolon TissueGene, Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hye Min Huh | iM Securities |
| Haejoo Wi | Korea Investment & Securities Co., Ltd. |
| Wan Ku | NH Investment & Securities Co., Ltd. |